In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company’s shares closed last Monday at $33.52.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 2.9% and a 37.1% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $78.44 average price target, implying a 131.2% upside from current levels. In a report issued on March 16, Cowen & Co. also maintained a Buy rating on the stock with a $87.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $76.98 and a one-year low of $24.82. Currently, Esperion has an average volume of 855.3K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
